Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study

Journal of Hypertension
A ZanchettiHans Wedel

Abstract

The Hypertension Optimal Treatment (HOT) Study provided information about cardiovascular events in 18,790 hypertensives, subjected to pronounced blood pressure lowering for a mean of 3.8 years. The HOT Study data have been further analysed after risk stratification of the patients (1999 World Health Organization and International Society of Hypertension guidelines criteria): (i) no patients of the HOT Study were classified as low risk, 50% were classified as medium risk, 20.2% as high risk and 29.8% as very high risk; (ii) incidence of cardiovascular events in these patients with excellent blood pressure control [92% had diastolic blood pressure (DBP) < or = 90 mmHg] remained proportional to pretreatment risk. The relative risk of very high- versus medium-risk strata was between two and three both when HOT Study patients were considered independently of, or within the DBP target group they had been randomized to; and (iii) event rates in all risk strata were calculated to be much lower (possibly 60% lower) than rates expected from baseline risk calculated approximately by the Framingham equation. The low event rate in HOT Study patients is likely to result from pronounced blood pressure lowering, and is not explained by a lower...Continue Reading

References

Jan 1, 1991·Circulation·K M AndersonW B Kannel
Oct 14, 1982·The New England Journal of Medicine·UNKNOWN Hypertension Detection and Follow-up Program Cooperative Group

❮ Previous
Next ❯

Citations

Apr 19, 2005·Der Internist·H Haller
Nov 1, 2005·Zeitschrift für Kardiologie·G BönnerG Sauer
Sep 17, 2003·Current Diabetes Reports·Elise Zimmerman, Judith Wylie-Rosett
Jul 16, 2002·Current Hypertension Reports·Hillel W Cohen, Michael H Alderman
Sep 9, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiromichi Suzuki, Kazuoki Kondo
Sep 15, 2004·PharmacoEconomics·Luca Degli Esposti, Giorgia Valpiani
Feb 28, 2006·Journal of Cardiac Failure· Heart Failure Society Of America
Feb 28, 2006·Journal of Cardiac Failure· Heart Failure Society Of America
May 12, 2009·BMC Endocrine Disorders·Sheldon W TobeRichard Z Lewanczuk
Jul 17, 2004·Journal of Hypertension·Martin Hausberg, Guido Grassi
Nov 17, 2004·Blood Pressure·Talma Rosenthal
Jun 7, 2005·Journal of the American Society of Nephrology : JASN·Giuseppe ManciaUNKNOWN European Society of Cardiology
Nov 1, 2002·Journal of Hypertension·Alberto ZanchettiUNKNOWN HOT Study Group
Oct 5, 2007·Revista española de cardiología·UNKNOWN Grupo de Trabajo para el Tratamiento de la Hipertensión Arterial de la Sociedad EuropeaJosé Luis Zamorano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.